Concalls & earnings callsPoly Medicure Limited

Every summarised call, newest first. Latest is Q1 FY27, held 10 Aug 2026.

Latest quarter

Q1 FY27 snapshot

PolyMed reported a strong start to its 'PolyMed 3.0 Ascent' phase with Q1 FY27 delivering revenue and EBITDA growth above guidance, driven by strategic acquisitions and a recovery in core segments.

Metric	This quarter	Change
Consolidated Revenue	₹525 Cr	30.3%
Consolidated Operating EBITDA	₹126.7 Cr	17.7%
Stand-alone Revenue	₹431 Cr	12.3%
Stand-alone Operating EBITDA	₹120.8 Cr	18.8%

Latest guidance

FY27 Consolidated Revenue: INR2,300-2,400 crores (includes full-year consolidation of PendraCare and Citieffe).
FY27 Stand-alone Revenue: INR1,900-2,000 crores (Domestic growth >20%, International growth >15%).
FY27 Stand-alone EBITDA Margin: 25%-27%.
FY27 Consolidated EBITDA Margin: 23%-25%.
FY27 Capex: INR200-225 crores.

Said on the Q1 FY27 call.

Filed results

Reported quarterly history

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

Quarter	Revenue	Net profit (PAT)	Basic EPS
Q3 FY25	₹424.21 Cr+24.9% YoY+1% QoQ	₹85.23 Cr+31.1% YoY-2.5% QoQ	₹8.48+25.1% YoY-5.9% QoQ
Q2 FY25	₹420.02 Cr+24.5% YoY+9.2% QoQ	₹87.45 Cr+40.6% YoY+18.1% QoQ	₹9.01+39% YoY+16.9% QoQ
Q1 FY25	₹384.78 Cr+19.9% YoY+1.8% QoQ	₹74.04 Cr+18.1% YoY+8.3% QoQ	₹7.71+17.9% YoY+8.3% QoQ
Q4 FY24	₹378.07 Cr+23.2% YoY+11.3% QoQ	₹68.36 Cr+16.2% YoY+5.1% QoQ	₹7.12+16.2% YoY+5% QoQ
Q3 FY24	₹339.60 Cr+19.2% YoY+0.7% QoQ	₹65.02 Cr+30% YoY+4.6% QoQ	₹6.78+30.1% YoY+4.6% QoQ

Call history

10 Aug 2026
Q1 FY27Positive tone
PolyMed reported a strong start to its 'PolyMed 3.0 Ascent' phase with Q1 FY27 delivering revenue and EBITDA growth above guidance, driven by strategic acquisitions and a recovery in core segments.
Consolidated Revenue
₹525 Cr30.3%
Consolidated Operating EBITDA
₹126.7 Cr17.7%
Pharmaceuticals & HealthcareVerified brief5 guidance items